Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

79P - Statins and immunotherapy: Togetherness makes strength - the potential effect of statins on immunotherapy for NSCLC

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Marco Filetti

Citation

Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392

Authors

M. Filetti1, A. Rossi2, M. Piras2, B. Taurelli Salimbeni2, F. Rizzo2

Author affiliations

  • 1 Sapienza, University of Rome, DPT Digestive and Liver Disease, Digestive Neuroendocrine Unit, Rome/IT
  • 2 Sapienza, University of Rome., Rome/IT
More

Abstract 79P

Background

Statins are commonly used agents in primary and secondary prevention of cardiovascular disease, but recent studies suggested that they can display pleiotropic effects on several cancer-related cellular processes, such as proliferation, apoptosis, angiogenesis, and metastasis. Even though the promising molecular features, results of RCTs investigating the combinations between statins and anticancer treatments have been controversial so far. A recent meta-analysis of observational studies and randomized clinical trials suggested that statins could positively affect the risk of all-cause mortality and improve OS in lung cancer patients. Preclinical studies suggested that these drugs could synergize with immunotherapy in the treatment of lung cancer. However, a large cohort study that could help validate these findings is still lacking in clinical practice. Given the encouraging in vitro and in vivo results of available evidence, we analyzed the data collected from 162 patients treated with immunotherapy for NSCLC in I and II-line setting.

Methods

In this observational study, we enrolled 162 patients who were treated at our institution between October 2015 and April 2020. All patients were candidate for immunotherapy, according to the tumor molecular profile. Descriptive statistics were used to analyze patients’ baseline features. Tumor response was evaluated using RECIST version 1.1 guidelines. Uni and multivariate analysis were conducted to investigate the relationship between statin use and response to ICI, using the χ2–test. Kaplan-Meier curves were used to estimate both OS and PFS in statin and non-statin users.

Results

Among all 162 screened patients, 122 met the requested criteria and were included in the final analysis. Median PFS was 17,57 months in the statin group and 9,57 months in the non-statin groupw (p=<0.001). Also, median OS was superior in the statin-users group, with a statistically significant difference (19,94 vs 10,94 months, p=<0.001).

Conclusions

We demonstrated a significant relationship between improved PFS and OS and statin use when compared to those achieved in non-statin users. Although interesting, this result needs to be validated with randomized clinical trials and larger cohorts.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.